Home
Storia in 4 fonti
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
- ·
cnbc.com
Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly's in trial
Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.
- ·
cincodias.elpais.com
Novo Nordisk vuelve a hundirse en Bolsa al fallar los ensayos de su nuevo medicamento contra la obesidad
La acción cae hasta un 16% y se deja ya un 75% desde mediados de 2024. El grupo danés se queda por detrás de su rival estadounidense Eli Lilly
- ·
theguardian.com
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations
- ·
Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades
Analysts raced to cut price targets on an already struggeling Novo Nordisk stock following disappointing trial results for its weight loss candidate CagriSema.
- ·
usatoday.com
Novo to cut Ozempic and Wegovy prices amid intense competition
Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.
- ·
Healthy Returns: What’s next for Novo Nordisk’s next-generation obesity drug CagriSema after trial miss
The Danish drugmaker released late-stage data showing that the upcoming injection CagriSema failed to match the weight loss of Eli Lilly’s Zepbound.